Mild Hypothermia in Acute Ischemic Stroke
Primary Purpose
Brain Ischemia
Status
Completed
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
Hypothermia
Sponsored by
About this trial
This is an interventional treatment trial for Brain Ischemia focused on measuring Stroke, Acute, Infarction, Ischemic, Thrombolysis, Mild, Hypothermia
Eligibility Criteria
Inclusion Criteria:
- Acute ischemic hemispheric stroke treated with Actilyse(tPA)-thrombolysis according to Meilahti protocol
- NIHSS 7-20 (after thrombolysis) or a significant paresis of arm or leg (NIHSS 3, no movement against gravity) or a significant dysphasia (NIHSS 2-3) despite of the total NIHSS score
- Symptom onset within 6 hour
Exclusion Criteria:
- Platelet count < 75,000/mm3
- Known coagulopathy (INR spontaneously >1.5)
- Hemodynamical unstability
- Recent history of angina pectoris or acute myocardial infarction
- Sepsis within 72 hours
- Pregnancy
- Pre-existing neurological disability with modified Rankin Scale Score>2
- Known allergy or intolerance to buspirone, dexmedetomidine, meperidine
- Intracranial hemorrhage in brain CT scan
- Intracranial mass lesion (i.e., abscess, tumor, or infection)
- Participation in an other therapy trial within last 3 months
- Hypothermia- treatment cannot be initiated within 6 hours of symptom onset
- Protocol violation in thrombolytic therapy
- Any condition where researchers assume that the patient is not suitable (must be reasoned)
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
Hypothermia
Control
Arm Description
Outcomes
Primary Outcome Measures
The proportion of patients maintaining temperature below 36.0°C 80% of the 12-hour hypothermia period.
Secondary Outcome Measures
The incidence of intracerebral hemorrhage, infections, hemodynamically significant cardiac arrhythmias, severe disturbance of electrolytes and fluid balance, thrombocytopenia, and serious adverse events
All-cause mortality during acute phase (7 days), 1 month, and 3 month follow-up; and readmission to hospital for any reason within 3-months.
The proportion of modified Rankin Scale-responders (mRS 0-2), Barthel Index, NIHSS, Glasgow Outcome Scale
Neuropsychological tests
Size of infarction in MRI, and grading of the possible hemorrhagic transformation according to SITS scale (MRI includes scout images, DWI, T1, T2, FLAIR, T2*, and MR angiography)
Full Information
NCT ID
NCT00987922
First Posted
September 30, 2009
Last Updated
September 17, 2011
Sponsor
University of Helsinki
1. Study Identification
Unique Protocol Identification Number
NCT00987922
Brief Title
Mild Hypothermia in Acute Ischemic Stroke
Official Title
Mild Hypothermia in Acute Ischemic Stroke After Thrombolytic Therapy: a Prospective,Open,Randomized,Single-center,Safety and Feasibility Study
Study Type
Interventional
2. Study Status
Record Verification Date
September 2011
Overall Recruitment Status
Completed
Study Start Date
July 2007 (undefined)
Primary Completion Date
September 2011 (Actual)
Study Completion Date
September 2011 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Helsinki
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Hypothesis: Mild hypothermia using non-invasive temperature management system in a stroke unit is safe and feasible in spontaneously breathing, alteplase-thrombolyzed patients with acute ischemic stroke.
Detailed Description
Fever is associated with higher stroke mortality and poor outcome, but it is yet unknown whether this association is causative or epiphenomenal.
In temporary brain ischemia rodent models hypothermia results in a significant increase in the number of surviving neurons and smaller infarction size as measured with histological examination after death.
Therapeutic effect has been shown in clinical trials in comatose cardiac arrest patients and newborn infants with perinatal hypoxic-ischemic brain injury.
Design: A prospective, open, randomized single-center study.
Study population: 36 patients, 18-85 years of age presenting with symptoms of acute ischemic hemispheric stroke with persisting significant neurological deficit (NIHSS 7-20 or NIHSS 2 for dysphasia or NIHSS 3 for paralysis of upper or lower limb) at 2 hours after thrombolysis.
Method: Patients are randomized to hypothermia- or control-group via randomization envelopes. Patients assigned to receive hypothermia are cooled to a core temperature of 35°C for 12 hours by means of a non-invasive temperature management system and cold i.v. fluids. Induction of hypothermia is initiated within 6 hours of symptom onset. After 12 hours of successful cooling the target temperature is gradually raised to achieve slow re-warming of 0.2°C/h until the core temperature reaches 36.8°C.
Patients are breathing spontaneously and shivering is controlled with following medication; dexmedetomidine 0.2-0.7 µg/kg/h (i.v.), buspirone 5-20 mg x 3 (nasogastric tube), and meperidine 25mg (i.v.) when needed.
Core temperature, blood pressure (BP), oxygen saturation, ECG and EEG are measured continuously and registered hourly. Blood tests will be taken before, during and after hypothermia. Brain CT will be controlled when normothermia is reached, no later than 30 hours from symptom onset. Brain MRI will be performed 3-7 days from symptom onset.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Brain Ischemia
Keywords
Stroke, Acute, Infarction, Ischemic, Thrombolysis, Mild, Hypothermia
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
36 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Hypothermia
Arm Type
Experimental
Arm Title
Control
Arm Type
No Intervention
Intervention Type
Device
Intervention Name(s)
Hypothermia
Intervention Description
Hypothermia to core temperature of 35C for 12 hours, rewarming rate 0.2C until the patient reaches 36.8C
Primary Outcome Measure Information:
Title
The proportion of patients maintaining temperature below 36.0°C 80% of the 12-hour hypothermia period.
Time Frame
12 hours
Secondary Outcome Measure Information:
Title
The incidence of intracerebral hemorrhage, infections, hemodynamically significant cardiac arrhythmias, severe disturbance of electrolytes and fluid balance, thrombocytopenia, and serious adverse events
Time Frame
14 days
Title
All-cause mortality during acute phase (7 days), 1 month, and 3 month follow-up; and readmission to hospital for any reason within 3-months.
Time Frame
3 months
Title
The proportion of modified Rankin Scale-responders (mRS 0-2), Barthel Index, NIHSS, Glasgow Outcome Scale
Time Frame
3 months
Title
Neuropsychological tests
Time Frame
3 months
Title
Size of infarction in MRI, and grading of the possible hemorrhagic transformation according to SITS scale (MRI includes scout images, DWI, T1, T2, FLAIR, T2*, and MR angiography)
Time Frame
3-7 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Acute ischemic hemispheric stroke treated with Actilyse(tPA)-thrombolysis according to Meilahti protocol
NIHSS 7-20 (after thrombolysis) or a significant paresis of arm or leg (NIHSS 3, no movement against gravity) or a significant dysphasia (NIHSS 2-3) despite of the total NIHSS score
Symptom onset within 6 hour
Exclusion Criteria:
Platelet count < 75,000/mm3
Known coagulopathy (INR spontaneously >1.5)
Hemodynamical unstability
Recent history of angina pectoris or acute myocardial infarction
Sepsis within 72 hours
Pregnancy
Pre-existing neurological disability with modified Rankin Scale Score>2
Known allergy or intolerance to buspirone, dexmedetomidine, meperidine
Intracranial hemorrhage in brain CT scan
Intracranial mass lesion (i.e., abscess, tumor, or infection)
Participation in an other therapy trial within last 3 months
Hypothermia- treatment cannot be initiated within 6 hours of symptom onset
Protocol violation in thrombolytic therapy
Any condition where researchers assume that the patient is not suitable (must be reasoned)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Markku Kaste, MD, PhD
Organizational Affiliation
Helsinki University Central Hospital
Official's Role
Principal Investigator
12. IPD Sharing Statement
Citations:
PubMed Identifier
24436240
Citation
Piironen K, Tiainen M, Mustanoja S, Kaukonen KM, Meretoja A, Tatlisumak T, Kaste M. Mild hypothermia after intravenous thrombolysis in patients with acute stroke: a randomized controlled trial. Stroke. 2014 Feb;45(2):486-91. doi: 10.1161/STROKEAHA.113.003180. Epub 2014 Jan 16.
Results Reference
derived
Learn more about this trial
Mild Hypothermia in Acute Ischemic Stroke
We'll reach out to this number within 24 hrs